Consensus document on spasticity in patients with multiple sclerosis;Documento de consenso sobre la espasticidad en pacientes con esclerosis múltiple

Revista de Neurologia

Volumn 57, Issue 8, 2013, Pages 359-373

  Oreja Guevara, Celia ^a   Montalban, Xavier ^b   de Andrés, Clara ^c   Casanova Estruch, Bonaventura ^d   Muñoz García, Delicias ^e   García, Inmaculada ^f   Fernández, Óscar ^g  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL XERAL CÍES   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Diagnosis; Multiple sclerosis; Nabiximols; Spasticity; Symptoms; Treatment

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CONSENSUS; DECISION MAKING; DEMYELINATING DISEASE; HUMAN; KNOWLEDGE; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE; QUALITY OF LIFE; SPASTICITY;

ALGORITHMS; CONTRACTURE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; OCCUPATIONAL THERAPY; ORTHOPEDIC EQUIPMENT; PARASYMPATHOLYTICS; PHYSICAL THERAPY MODALITIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84885761974     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5708.2013374     Document Type: Article

References (141)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
2. Samkoff LM GA. Symptomatic management in multiple sclerosis. Neurol Clin 2011; 29: 449-63.
3. De Sa JC, Airas L, Bartholome E, Grigoriadis N, Mattle H, Oreja-Guevara C, et al. Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord 2011; 4: 139-68.
4. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13: 700-22.
5. Ares B PJ, Lema M, Dapena D, Arias M, Noya M. Prevalence of multiple sclerosis in Santiago de Compostela (Galicia, Spain). Mult Scler 2007; 13: 262-4.
6. Morís G, Berciano J, Miró J. A clinical longitudinal study of multiple sclerosis in Cantabria, Spain. Neurología 2003; 18: 723-30.
7. Modrego Pardo PJ, Latorre MA, Lopez A, Errea JM. Prevalence of multiple sclerosis in the province of Teruel, Spain. J Neurol 1997; 244: 182-5.
8. Aladro Y, Alemany MJ, Pérez-Vieitez MC, Amela R, Conde M, Reyes MP, et al. Prevalence and incidence of multiple sclerosis in Las Palmas, Canary Islands, Spain. Neuroepidemiology 2005; 24: 70-5.
9. Otero-Romero S, Roura P, Solà J, Altimiras J, Sastre-Garriga J, Nos C, et al. Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain. Mult Scler 2013; 19: 245-8.
10. Fernández O, Fernández V, Guerrero M, León A, López-Madrona JC, Alonso A, et al. Multiple sclerosis prevalence in Malaga, Southern Spain estimated by the capture-recapture method. Mult Scler 2012; 18: 372-6.
11. Hartung HP. Advances in the management of multiple sclerosis-related spasticity. Expert Rev Neurother 2012; 12: 1.
12. Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 205-13.
13. Garreta-Figuera R, Chaler-Vilaseca J, Torrequebrada-Giménez A. Guía de práctica clínica del tratamiento de la espasticidad con toxina botulínica. Rev Neurol 2010; 50: 685-99.
14. Vivancos-Matellano F, Pascual-Pascual SI, Nardi-Vilardaga J, Miquel-Rodríguez F, De Miguel-León I, Martínez-Garre MC, et al. Guía del tratamiento integral de la espasticidad. Rev Neurol 2007; 45: 365-75.
15. Murie M, Moral E. Espasticidad en esclerosis múltiple. Madrid: Equalmás 5; 2011.
16. Paisley S, Beard S, Hunn A, Wight J. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler 2002; 8: 319-29.
17. Multiple Sclerosis Australia. Spasticity and multiple sclerosis. Practice for health professionals. URL: http://www.msaustralia. org.au.
18. Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. Neurology 1980; 30: 1303-13.
19. Young RR. Spasticity: a review. Neurology 1994; 44: S12-20.
20. Elbasiouny SM, Moroz D, Bakr MM, Mushahwar VK. Management of spasticity after spinal cord injury: current techniques and future directions. Neurorehabil Neural Repair 2010; 24: 23-33.
21. Young RR, Delwaide PJ. Drug therapy: spasticity (first of two parts). N Engl J Med 1981; 304: 28-33.
22. Brown P. Pathophysiology of spasticity. J Neurol Neurosurg Psychiatry 1994; 57: 773-7.
23. Gracies JM. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve 2005; 31: 552-71.
24. Thompson PD. Rigidity and spasticity. In Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Baltimore: Williams & Wilkins; 1998. p. 755-62.
25. Fahn S. Generalized dystonia: concept and treatment. Clin Neuropharmacol 1986; 9 (Suppl 2): S37-48.
26. Verplancke D, Snape S, Salisbury CF, Jones PW, Ward AB. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 2005; 19: 117-25.
27. Herring J. Disorders of the brain. In Herring J, ed. Tachdjian's pediatric orthopaedics. Chicago: Saunders; 2002. p. 1122-242.
28. Miller F. Cerebral palsy. New York: Springer-Verlag; 2005.
29. Munuera L. Fisiopatología del aparato de crecimiento. In Munuera L, ed. Introducción a la traumatología y cirugía ortopédica. México: McGraw-Hill/Interamericana; 1997. p. 118-31.
30. Emery D, Wedge J. Orthopaedic management of children with total body involvement cerebral palsy. Mini symposium: cerebral palsy. Curr Orthop 2003; 17: 81-7.
31. Martín-Barriga ML, Martínez ML, De Andrés C. Tratamiento sintomático del dolor, los trastornos paroxísticos, los trastornos motores y la espasticidad en pacientes con esclerosis múltiple. In Prieto-González JM, Arbizu T, eds. Monografías en esclerosis múltiple. Madrid: Acción Médica; 2009.
32. Aguilar-Barberá M, Bori-Fortuny I, García-Aymerich V, García-Ruiz Espiga PJ, Garreta-Figuera R, Herrera-Galante A, et al. Guía terapéutica de la espasticidad del adulto con toxina botulínica. Rev Neurol 2004; 38: 971-8.
33. Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM 2004; 97: 671-6.
34. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004; 10: 589-95.
35. Oreja-Guevara C, Gonzalez-Segura D, Vila C. Spasticity in multiple sclerosis: results of a patient survey. Int J Neurosci 2013; 123: 400-8.
36. Haselkorn JK, Balsdon Richer C, Fry Welch D, Herndon RM, Johnson B, Little JW, et al. Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med 2005; 28: 167-99.
37. Bavikatte G, Gaber T. Approach to spasticity in general practice. Br J Med Pract 2009; 2: 29-34.
38. Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 2009; 26: 1043-57.
39. UNICEF. VIPP: Visualisation in Participatory Planning. Dhaka: UNICEF; 1993.
40. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-2.
41. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206-7.
42. Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H. A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil 1999; 13: 373-83.
43. Pandyan AD, Price CI, Barnes MP, Johnson GR. A biomechanical investigation into the validity of the modified Ashworth Scale as a measure of elbow spasticity. Clin Rehabil 2003; 17: 290-3.
44. Fleuren JF, Voerman GE, Erren-Wolters CV, Snoek GJ, Rietman JS, Hermens HJ, et al. Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 2010; 81: 46-52.
45. Ghotbi N, Ansari NN, Naghdi S, Hasson S, Jamshidpour B, Amiri S. Inter-rater reliability of the Modified Ashworth Scale in assessing lower limb muscle spasticity. Brain Inj 2009; 23: 815-9.
46. Ghotbi N, Nakhostin Ansari N, Naghdi S, Hasson S. Measurement of lower-limb muscle spasticity: intrarater reliability of Modified Ashworth Scale. J Rehabil Res Dev 2011; 48: 83-8.
47. Ansari NN, Naghdi S, Arab TK, Jalaie S. The interrater and intrarater reliability of the Modified Ashworth Scale in the assessment of muscle spasticity: limb and muscle group effect. NeuroRehabilitation 2008; 23: 231-7.
48. Sloan RL, Sinclair E, Thompson J, Taylor S, Pentland B. Inter-rater reliability of the modified Ashworth Scale for spasticity in hemiplegic patients. Int J Rehabil Res 1992; 15: 158-61.
49. Platz T, Eickhof C, Nuyens G, Vuadens P. Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. Disabil Rehabil 2005; 27: 7-18.
50. Blackburn M, Van Vliet P, Mockett SP. Reliability of measurements obtained with the modified Ashworth scale in the lower extremities of people with stroke. Phys Ther 2002; 82: 25-34.
51. Haas BM, Bergstrom E, Jamous A, Bennie A. The inter rater reliability of the original and of the modified Ashworth scale for the assessment of spasticity in patients with spinal cord injury. Spinal Cord 1996; 34: 560-4.
52. Craven BC, Morris AR. Modified Ashworth scale reliability for measurement of lower extremity spasticity among patients with SCI. Spinal Cord 2010; 48: 207-13.
53. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008; 30: 974-85.
54. Anwar K, Barnes MP. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. NeuroRehabilitation 2009; 24: 333-40.
55. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517-21.
56. Biering-Sorensen F, Nielsen JB, Klinge K. Spasticity-assessment: a review. Spinal Cord 2006; 44: 708-22.
57. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28: 512-5.
58. Laessoe L, Nielsen JB, Biering-Sorensen F, Sonksen J. Antispastic effect of penile vibration in men with spinal cord lesion. Arch Phys Med Rehabil 2004; 85: 919-24.
59. Boviatsis EJ, Kouyialis AT, Korfias S, Sakas DE. Functional outcome of intrathecal baclofen administration for severe spasticity. Clin Neurol Neurosurg 2005; 107: 289-95.
60. Gianino JM, York MM, Paice JA, Shott S. Quality of life: effect of reduced spasticity from intrathecal baclofen. J Neurosci Nurs 1998; 30: 47-54.
61. Gómez-Soriano J, Cano-de-la-Cuerda R, Muñoz-Hellín E, Ortiz-Gutiérrez R, Taylor JS. Valoración y cuantificación de la espasticidad: revisión de los métodos clínicos, biomecánicos y neurofisiológicos. Rev Neurol 2012; 55: 217-26.
62. Priebe MM, Sherwood AM, Thornby JI, Kharas NF, Markowski J. Clinical assessment of spasticity in spinal cord injury: a multidimensional problem. Arch Phys Med Rehabil 1996; 77: 713-6.
63. Simeoni M, Auquier P, Fernández O, Flachenecker P, Stecchi S, Constantinescu C, et al; MusiQol study group. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler 2008; 14: 219-30.
64. Fernández O, Fernández V, Baumstarck-Barrau K, Muñoz L, González-Álvarez MM, Arrabal JC, et al. Validation of the Spanish version of the Multiple Sclerosis International Quality of Life (Musiqol) questionnaire. BMC Neurol 2011; 11: 127.
65. Kabus C, Hecht M, Japp G, Jost WH, Pohlau D, Stuckrad-Barre S, et al. Botulinum toxin in patients with multiple sclerosis. J Neurol 2006; 253 (Suppl 1): I26-8.
66. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003; 7: 1-111.
67. Pappalardo F. Pharmacologic management of spasticity in multiple sclerosis. Neurol Sci 2006; 27: S310-5.
68. Dones I, Nazzi V, Broggi G. The guidelines for the diagnosis and treatment of spasticity. J Neurosurg Sci 2006; 50: 101-5.
69. Oreja-Guevara C. Tratamiento de la espasticidad en la esclerosis múltiple: nuevas perspectivas con el uso de cannabinoides. Rev Neurol 2012; 55: 421-30.
70. Oreja-Guevara C. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosisrelated spasticity. Expert Rev Neurother 2012; 12: 3-8.
71. Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Mult Scler 2012; 18: 219-28.
72. Robson P. Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011; 10: 675-85.
73. Young R DP. Drug therapy, spasticity. N Engl J Med 1981; 304.
74. Brashear A, Lambeth K. Spasticity. Curr Treat Options Neurol 2009; 11: 153-61.
75. Brin MF AR. Botulinum toxin type A: pharmacology. In Mayer MH, Simpson DM, eds. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York: We Move; 2002. p. 110-24.
76. Ryll U, Bastiaenen C, De Bie R, Staal B. Effects of leg muscle botulinum toxin A injections on walking in children with spasticity-related cerebral palsy: a systematic review. Dev Med Child Neurol 2011; 53: 210-6.
77. Mueller ME, Gruenthal M, Olson WL, Olson WH. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Rehabil 1997; 78: 521-4.
78. Montane E, Vallano A, Laporte JR. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology 2004; 63: 1357-63.
79. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003; 4: CD001332.
80. Rekand T. Clinical assessment and management of spasticity: a review. Acta Neurol Scand Suppl 2010; 190: 62-6.
81. Kushner S. Spasticity. Clinical bulletin information for health professionals. New York: National Multiple Sclerosis Society; 2012.
82. Dario A, Tomei G. A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf 2004; 27: 799-818.
83. Pedersen E, Arlien-Soborg P, Grynderup V, Henriksen O. GABA derivative in spasticity. (Beta-(4-chlorophenyl)-gammaaminobutyric acid, Ciba 34.647-Ba). Acta Neurol Scand 1970; 46: 257-66.
84. Dietrichson P. Lioresal 'Ciba' (baclofen). A new antispasmodic drug. Tidsskr Nor Laegeforen 1972; 92: 2352-3.
85. Pinto Ode S, Polikar M, Debono G. Results of international clinical trials with Lioresal. Postgrad Med J 1972; 48 (Suppl 5): 18-25.
86. Jones RF, Lance JW. Bacloffen (Lioresal) in the long-term management of spasticity. Med J Aust 1976; 1: 654-7.
87. Simon O, Yelnik AP. Managing spasticity with drugs. Eur J Phys Rehabil Med 2010; 46: 401-10.
88. United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994; 44: S70-8.
89. Smith MB, Brar SP, Nelson LM, Franklin GM, Cobble ND. Baclofen effect on quadriceps strength in multiple sclerosis. Arch Phys Med Rehabil 1992; 73: 237-40.
90. Jerusalem F. Double-blind study on the antispastic effect of beta-94-chlorphenyl)-gamma aminobutyric acid (CIBA) in multiple sclerosis. Nervenarzt 1968; 39: 515-7.
91. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994; 44: S34-43.
92. Sawa GM, Paty DW. The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci 1979; 6: 351-4.
93. Sachais BA, Logue JN, Carey MS. Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol 1977; 34: 422-8.
94. Duncan GW, Shahani BT, Young RR. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study. Neurology 1976; 26: 441-6.
95. Feldman RG, Kelly-Hayes M, Conomy JP, Foley JM. Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. Neurology 1978; 28: 1094-8.
96. Hudgson P, Weightman D. Baclofen in the treatment of spasticity. Br Med J 1971; 4: 15-7.
97. Milanov I, Georgiev D. Mechanisms of tizanidine action on spasticity. Acta Neurol Scand 1994; 89: 274-9.
98. Kamen L, Henney HR 3rd, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin 2008; 24: 425-39.
99. Lapeyre E, Kuks JB, Meijler WJ. Spasticity: revisiting the role and the individual value of several pharmacological treatments. NeuroRehabilitation 2010; 27: 193-200.
100. Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther 1998; 15: 241-51.
101. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculo-skeletal conditions: a systematic review. J Pain Symptom Manage 2004; 28: 140-75.
102. Bes A, Eyssette M, Pierrot-Deseilligny E, Rohmer F, Warter JM. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin 1988; 10: 709-18.
103. Schmidt RT, Lee RH, Spehlmann R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1976; 39: 350-6.
104. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434-41.
105. Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol 2009; 9: 59.
106. Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010; 16: 707-14.
107. Ambler Z, Davies P, Gasperini C. A two-phase study of Sativex in the relief of spasticity due to multiple sclerosis: phase A single-blind response assessment followed by phase B double-blind, randomised, placebo-controlled, parallel-group study. Mult Scler 2009; 15: S258.
108. Montalban X, Wright S. Trial period for new symptomatic treatments: lessons learnt from a Sativex in MS spasticity clinical trial [abstract]. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Dusseldorf, Alemania, septiembre de 2009.
109. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double-blind, placebocontrolled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122-31.
110. Burchiel KJ, Hsu FP. Pain and spasticity after spinal cord injury: mechanisms and treatment. Spine 2001; 26: S146-60.
111. Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs 2000; 59: 487-95.
112. Francisco GE, Yablon SA, Schiess MC, Wiggs L, Cavalier S, Grissom S. Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. Topics Stroke Rehabil 2006; 13: 74-85.
113. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306-10.
114. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002; 347: 395-400.
115. Brin M, Aoki R. Botulinum toxin type A: pharmacology. In Mayer MH, Simpson DM, eds. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York: We Move; 2002. p. 110-24.
116. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity and immunology. Muscle Nerve 1997; 6: S146-68.
117. Yelnik AP, Simon O, Bensmail D, Chaleat-Valayer E, Decq P, Dehail P, et al. Drug treatments for spasticity. Ann Phys Rehabil Med 2009; 52: 746-56.
118. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A; BoNT/TZD Study Team. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry 2009; 80: 380-5.
119. Bakheit AM, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001; 8: 559-65.
120. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000; 31: 2402-6.
121. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and career burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000; 69: 217-21.
122. Bhakta BB, O'Connor RJ, Cozens JA. Associated reactions after stroke: a randomized controlled trial of the effect of botulinum toxin type A. J Rehabil Med 2008; 40: 36-41.
123. Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 2008; 89: 799-806.
124. Francisco GE, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil 2002; 81: 355-63.
125. Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J, et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004; 63: 1971-3.
126. Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, doubleblind, placebo-controlled trial. Clin Rehabil 1998; 12: 381-8.
127. Kong KH, Neo JJ, Chua KS. A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity. Clin Rehabil 2007; 21: 28-35.
128. Lim JY, Koh JH, Paik NJ. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke 2008; 39: 126-31.
129. Marco E, Duarte E, Vila J, Tejero M, Guillén A, Boza R, et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. J Rehabil Med 2007; 39: 440-7.
130. Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol 2002; 249: 76-84.
131. Smith SJ, Ellis E, White S, Moore AP. A double-blind placebocontrolled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000; 14: 5-13.
132. Yelnik AP, Colle FM, Bonan IV, Vicaut E. Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A. J Neurol Neurosurg Psychiatry 2007; 78: 845-8.
133. Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm 2008; 115: 617-23.
134. Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix X, Joseph PA, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996; 61: 265-9.
135. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 68: 707-12.
136. Rousseaux M, Compere S, Launay MJ, Kozlowski O. Variability and predictability of functional efficacy of botulinum toxin injection in leg spastic muscles. J Neurol Sci 2005; 232: 51-7.
137. Yelnik A, Colle F, Bonan I, Bradai N. Efficacy at six months of the botulinum toxin A in the post-stroke lower limb's muscular overactivity. Ann Readapt Med Phys 2002; 45: 159-65.
138. Porter B. A review of intrathecal baclofen in the management of spasticity. Br J Nurs 1997; 6: 253-60, 62.
139. Sadiq SA, Wang GC. Long-term intrathecal baclofen therapy in ambulatory patients with spasticity. J Neurol 2006; 253: 563-9.
140. Hsieh JC, Penn RD. Intrathecal baclofen in the treatment of adult spasticity. Neurosurg Focus 2006; 21: e5.
141. Erwin A, Gudesblatt M, Bethoux F, Bennett SE, Koelbel S, Plunkett R, et al. Intrathecal baclofen in multiple sclerosis: too little, too late? Mult Scler 2011; 17: 623-9.